Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial.

Wechsler ME, Brightling CE, Brusselle G, Caminati M, Soler T, González EM, Nakwan N, Capala-Szczurko I, Hunter G, Almqvist G, Lal H, Kabelis P, Scrigner P, Matsunaga Y, Molfino N, Ponnarambil SS, SUNRISE study investigators.

Open source

DOI: 10.1016/s2213-2600(26)00076-7
Published: 2026-05-18
Container: Lancet Respir Med
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2213-2600-26-00076-7,
  title = {Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial.},
  author = {Wechsler ME and  Brightling CE and  Brusselle G and  Caminati M and  Soler T and  González EM and  Nakwan N and  Capala-Szczurko I and  Hunter G and  Almqvist G and  Lal H and  Kabelis P and  Scrigner P and  Matsunaga Y and  Molfino N and  Ponnarambil SS and  SUNRISE study investigators.},
  year = {2026},
  journal = {Lancet Respir Med},
  doi = {10.1016/s2213-2600(26)00076-7},
  url = {https://doi.org/10.1016/s2213-2600(26)00076-7}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial.
AU  - Wechsler ME
AU  -  Brightling CE
AU  -  Brusselle G
AU  -  Caminati M
AU  -  Soler T
AU  -  González EM
AU  -  Nakwan N
AU  -  Capala-Szczurko I
AU  -  Hunter G
AU  -  Almqvist G
AU  -  Lal H
AU  -  Kabelis P
AU  -  Scrigner P
AU  -  Matsunaga Y
AU  -  Molfino N
AU  -  Ponnarambil SS
AU  -  SUNRISE study investigators.
PY  - 2026
JO  - Lancet Respir Med
DO  - 10.1016/s2213-2600(26)00076-7
UR  - https://doi.org/10.1016/s2213-2600(26)00076-7
ER  -

APA

ME, W., CE, B., G, B., M, C., T, S., EM, G., N, N., I, C., G, H., G, A., H, L., P, K., P, S., Y, M., N, M., SS, P., & investigators., S. S. (2026). Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial.. Lancet Respir Med. https://doi.org/10.1016/s2213-2600(26)00076-7

Source records

europe-pmc · retrieved 2026-09-26T21:04:33.314Z